Abu Dhabi Health Data Services Partners With Syndesis Health To Enhance AI-Driven Genomic Analytics And Drug Discovery

Abu Dhabi Health Data Services (ADHDS), part of M42’s Digital Health Solutions platform, has entered into a partnership with Syndesis Health. This collaboration unites one of the largest phenotype data holders globally, with over 70 million patient profiles, and ADHDS’s advanced digital health infrastructure. The agreement was signed by Kareem Shahin, CEO of M42’s Digital Health Solutions, and Josh Sutton, CEO of Syndesis Health.

The partnership aims to revolutionise AI-powered genomic analytics, precision medicine, and drug discovery. By integrating real-world data with sophisticated artificial intelligence, the collaboration seeks to enhance clinical decision support and pharmaceutical research. This initiative is expected to improve treatment pathways for patients worldwide.

The collaboration will focus on three main areas: commercialising phenotype data to aid global pharmaceutical, biotech, and academic research; developing AI-driven predictive models for personalised healthcare while adhering to international data governance standards; and enhancing genomic analytics to improve prescription safety through AI-powered pharmacogenomics.

Kareem Shahin highlighted the importance of this partnership by stating, "This collaboration represents a major step forward in harnessing real-world data and AI to transform healthcare. By integrating Syndesis Health’s vast phenotype dataset with our digital health expertise, we are opening new frontiers in genomic analytics and drug discovery."

Advancing Global Healthcare

Josh Sutton added that the collaboration will produce groundbreaking insights that accelerate pharmaceutical innovation and improve patient outcomes. He stated, "Together, we are setting new benchmarks for AI-driven healthcare solutions." This partnership is a significant milestone in advancing precision medicine and AI-powered drug discovery.

By leveraging their complementary strengths, both parties have signed a term sheet outlining their intent to form a joint venture. This venture aims to generate valuable insights that will speed up drug development, enhance patient outcomes, and support the growth of healthcare infrastructure. The collaboration aligns with Abu Dhabi's vision of becoming a leader in digital health and biomedical research.

With a shared commitment to advancing global healthcare through data-driven innovation, this partnership marks an important step in the evolution of precision medicine.

With inputs from WAM